detected by STE during therapy appeared to be the most useful parameter for the prediction of cardiotoxicity, defined as a drop in LV ejection fraction (LVEF) or heart failure. [6] LV GLS by STE and right ventricular (RV) tricuspid annular plane systolic excursion (TAPSE) by TDI are recommended parameters by the American Society of Echocardiography (ASE) and the European Association of Cardiovascular Imaging (EACVI). [7] The aim of the study was to detect and evaluate sensitive parameters using TDI and 2D-STE for subclinical cardiotoxicity caused by anthracyclines' chemotherapy, which affects biventricular function among children with solid tumor.
Methods

Ethical approval
The study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Beijing Tongren Hospital. Informed consent was obtained from their legal guardians of these patients and healthy controls.
Subjects and protocols
This study included 36 asymptomatic children with hepatoblastoma (HB) or rhabdomyosarcoma (RMS), who were referred to Beijing Tongren Hospital for chemotherapy from January 2015 to December 2016. Thirty-six healthy children for routine check-up who had no congenital cardiovascular disease were collected as healthy controls. These patients were all subjected to detailed medical history and general and cardiac examinations. Treatment protocols used were those recommended by the pediatric department according to the type of solid tumor. HB patients were given chemotherapy protocols with "pirarubicin (25 mg/m 2 , day 1-3) + cyclophosphamide (800-1000 mg/m 2 , day 1) + cisplatin (90 mg/m 2 , day 1)" or "pirarubicin (25 mg/m 2 , day 1-3) + etoposide (100 mg/m 2 , day 1-4) + cisplatin (90 mg/m 2 , day 1)". RMS patients were given chemotherapy protocols with "pirarubicin (25 mg/m 2 , days 2 and 9) + vincristine (1.5 mg/m 2 , days 1 and 8) + cyclophosphamide (300 mg/m 2 , days 1-3) + cisplatin (90 mg/m 2 , day 1)" or "ifosfamide (1.5 g/m 2 , day 1-5 + dactinomycin (12-15 µg/kg, day 1-5) + etoposide (100 mg/m 2 , day 1-3) + vincristine (1.5 mg/m 2 , day 1 and day 8)". These patients had no congenital cardiovascular disease or the cardiovascular system metastases, and no other cardiotoxic drugs administered. The duration of therapy was >1 year and all patients were in complete remission at the time of the study. Age and gender of 36 healthy controls were matched with patients. Thirty-six patients were divided into two subgroups according to anthracyclines' cumulative dosage: <300 mg/m 2 subgroup and ≥300 mg/m 2 subgroup.
Echocardiographic study
Transthoracic echocardiography was performed in all patients after the last chemotherapy session by the same sonographer. The healthy controls received the same examination. LV dimensions and LVEF were measured in parasternal long axis view, and TAPSE of the RV lateral wall was measured in apical four-chamber view, all of them were acquired by M-mode. [8] Pulsed wave Doppler velocity was used to measure the mitral inflow E velocity and A velocity. The early diastolic peak velocity of transmitral flow (E) was measured at mitral valve. TDI measurements included septal diastolic e' mitral annular peak velocity (e') and septal systolic s' mitral annular peak velocity (s'). The ratio of E and e' (E/e') was also calculated.
The 2D-STE was performed for the left ventricle. The 2D images were obtained in the apical four-chamber, apical long-axis, and apical two-chamber views to measure the longitudinal deformation. A frame rate of 60 Hz was used because it is considered optimal for 2D-STE. [9] Acceptable images from three cardiac cycles were digitally saved in cine loop format on the hard disc of the echo machine and subsequently exported to a digital versatile disc and imported into the postprocessing station (EchoPAC version 201, General Electric Co., USA) for offline analysis. Cardiac cycles with lengths >10% of mean length of the three cardiac cycles were excluded from further analysis, and manual tracking of the endocardial borders was performed. The timing of aortic valve closure was also manually determined. Tracking data were accepted if the EchoPAC software showed adequate tracking and if the examiner's inspection revealed good tracking throughout the cardiac cycle. Autofunctional imaging was used to enable the assessment of the systolic segmental and GLS. Segmental longitudinal strain was calculated using 17-segment bull's eye. The LV GLS was calculated by the mean GLS of the apical four-chamber and two-chamber views and apical long-axis view.
Statistical analysis
Statistical analysis was performed using Statistical Package for the Social Sciences software (version 21.0; SPSS Inc., Chicago, Illinois, USA). Data were tested for normality using Kolmogorov-Smirnov test and were expressed as a mean ± standard deviation (SD), and categorical data were showed as percentages. Comparisons between the groups were calculated using nonparametric tests (Wilcoxon's test) for nonnormally distributed data and parametric tests (t-test) for normally distributed data. The intra-and inter-observer variabilities for LV GLS and TASPE were assessed in twenty randomly selected patients by one examiner on two separate occasions. Bland-Altman plot analysis was used to determine the mean intraobserver differences. [10] A P < 0.05 was considered statistically significant.
Results
Clinical characteristics
The patient group included 24 boys and 12 girls. Twenty-six patients were diagnosed as HB, and ten were diagnosed as RMS. In patient group, the mean age was 3.6 ± 2.2 years and the mean weight was 18.3 ± 7.3 kg. The mean height was 106.6 ± 25.0 cm and the mean body surface area was 0.7 ± 0.2 m 2 . All patients received anthracyclines in the form of pirarubicin, and the anthracyclines' cumulative dosage ranged from 24.8 mg/m 2 to 772.0 mg/m 2 . The mean value of accumulative anthracyclines' dosage was 293.7 ± 35.4 mg/m 2 . There were 21 patients in the subgroup with cumulative anthracyclines' dosage <300 mg/m 2 and 15 patients in the subgroup with cumulative anthracyclines' dosage ≥300 mg/m 2 . Control group included 20 boys and 16 girls. The mean age of healthy controls was 3.9 ± 2.2 years, the mean weight was 19.7 ± 7.9 kg, the mean height was 108.1 ± 9.6 cm, and the mean body surface area was 0.7 ± 0.2 m 2 . There were no significant differences in age, weight, height, and body surface between the patient and control groups (all P > 0.05).
Left and right ventricular dysfunction after chemotherapy
After anthracyclines' chemotherapy, the patient group had no presentation of heart failure and had mean LVEF within the normal range of 65.7 ± 5.1%, compared with healthy controls (66.6 ± 3.4%, P = 0.52). However, the mean E/e' increased significantly in the patient group (10.2 ± 3.5 vs. 7.9 ± 0.7, P < 0.01), compared with healthy controls. The mean s' had no significant difference between the patient group and control groups (6.9 ± 1.4 vs. 7.0 ± 1.1, P = 0.92).
Mean LV GLS was −17.9 ± 2.9% in the patient group and −22.2 ± 1.9% in healthy controls, and there was a significant difference (P < 0.01). The mean LV GLS from the apical long-axis, four-chamber, and two-chamber views in the patient and control groups is presented in Table 1 . Images of LV GLS were presented in Figures 1-3 , which illustrated the different GLS changes obtained from the apical long-axis view, four-chamber view, two-chamber-view, and strain curves and bull's eye plot in three patients after receiving pirarubicin treatment.
Mean TAPSE decreased significantly in patient group, compared with healthy controls (14.2 ± 3.0 mm vs. 17.2 ± 1.3 mm, P < 0.01).
Comparison of left ventricular global longitudinal strain, E/e', and tricuspid annular plane systolic excursion according to different anthracyclines' cumulative dosage
Mean LVEF between the two subgroups of patients had no significant difference (65.9 ± 5.5% vs. 66.5 ± 4.6%, P = 0.83). The mean LV GLS decreased significantly (−16.5 ± 2.1% vs. −18.7 ± 2.7%, P = 0.04), the mean E/e' increased significantly (11.5 ± 4.9 vs. 9.1 ± 1.5, P = 0.04), and mean TAPSE decreased significantly (12.5 ± 2.2 mm vs. 14.2 ± 2.1 mm, P = 0.02) in subgroup with anthracyclines' cumulative dosage ≥300 mg/m 2 , compared with subgroup with anthracyclines' cumulative dosage <300 mg/m 2 [ Table 2 ].
dIscussIon
Clinical effectiveness of anthracyclines may be thwarted by the development of cardiotoxicity that negatively affects patients' outcomes and seriously limits their oncological The data were shown as mean ± SD. LVEF: Left ventricular ejection fraction; E/e': The ratio of early diastolic peak velocity of transmitral flow (E) and septal diastolic e' mitral annular peak velocity (e'); s': Septal systolic s' mitral annular peak velocity; TAPSE: Tricuspid annular plane systolic excursion; GLS: Global longitudinal strain; LAX: Apical long-axis view; 4CH: Four-chamber view; 2CH: Two-chamber view; SD: Standard deviation. 02 The data were shown as mean ± SD. LVEF: Left ventricular ejection fraction; GLS: Global longitudinal strain; E/e': The ratio of early diastolic peak velocity of transmitral flow (E) and septal diastolic e' mitral annular peak velocity (e'); TAPSE: Tricuspid annular plane systolic excursion; SD: Standard deviation. therapeutic opportunities. [11, 12] Cancer survivors tend to develop heart failure, ischemic heart disease, and cerebrovascular incidents more often than the general population. The cardiovascular mortality among childhood cancer survivors was 10-fold higher than those of age-matched healthy controls. [13, 14] Detection of an obviously decreased LVEF after anthracyclines' administration might be too late for treatment, suggesting that more sensitive parameters would be helpful for detecting left and RV dysfunction. [15] To detect LV systolic dysfunction in anthracyclines cardiotoxicity, a report from the ASE and the EACVI recommended as follows: LVEF assessed by 2D echocardiography often fails to detect small changes in LV contractility, and LVEF should be combined with wall motion score index. In the absence of GLS by STE, quantification of LV longitudinal function using mitral annular displacement by M-mode echocardiography and/or peak systolic velocity (s') of the mitral annulus by pulsed wave TDI is recommended. [7] Numerous reports about LV GLS in adults those received anthracyclines' treatment existed; [16, 17] however, only a few such studies have been conducted in children. [18, 19] Results mostly showed that LV GLS was sensitive enough to identify subclinical cardiotoxicity. Hence, we chose GLS and s' to detect subclinical cardiotoxicity of LV. After anthracyclines' chemotherapy, conventional echocardiography of LVEF showed normal findings. The mean LVEF was 65.7 ± 5.1% in the patient group with anthracyclines' chemotherapy, while the mean LVEF in healthy controls was 66.6 ± 3.4%, without significant difference. However, mean LV GLS in patient group was much lower than that of the healthy controls (−17.9 ± 2.9% vs. −22.2 ± 1.9%, P < 0.01). The mean LV GLS in healthy children was −22.2 ± 1.9%, which was in accordance with the recommended universal normal value (−22.1 ± 2.4%) or lower limits of the normal range. [9, 20] However, the difference of mean s' between the two groups showed no significant difference (6.9 ± 1.4 vs. 7.0 ± 1.1, P = 0.92). The difference of mean s' in this study might be affected by the size of sample, which will be further investigated in large sample study to make sure its clinical value. Thus, LV GLS changed apparently earlier than the LVEF and s', which was a sensitive subclinical parameter for cardiotoxicity in children.
A comprehensive assessment of LV diastolic function should also be performed, including the ratio of E and e', which could be an index of LV diastolic function according to the joint recommendations of ASE and European Association of Echocardiography. [21] Thus, this study chose the ratio of E and e' to evaluate the diastolic function of LV. Results showed that E/e' had a significant difference between the patient group and healthy controls. Therefore, the E/e' could be a parameter to identify subclinical LV diastolic Moreover, TAPSE was another parameter recommended to detect RV systolic function, and it reflected systolic function of right ventricle. [7] Results of this study showed that an obvious reduction in TAPSE in the patient group, compared with healthy controls. The RV systolic function also appeared abnormal after anthracyclines' chemotherapy, and TAPSE had a significant decrease before LVEF change.
In 26% of patients who received low-to-moderate dosage of anthracyclines (50-375 mg/m 2 ), evidence of subclinical cardiac injury was noted within 6 months after therapy of anthracyclines. [22] Abnormal GLS was correlated with the dose ≥300 mg/m 2 . [23] Hence, patients in this study were divided into two subgroups: <300 mg/m 2 subgroup and ≥300 mg/m 2 subgroup. The LV GLS decreased significantly in subgroup with anthracyclines' cumulative dosage ≥300 mg/m 2 , compared with subgroup with anthracyclines' cumulative dosage <300 mg/m 2 . When LVEF had no significant difference between the two subgroups, LV GLS had the significant difference, which might imply that LV GLS could change according to the cumulative dosage. In the future, a study with large sample size will be conducted to make clear that if the change of LV GLS has a linear correlation with anthracyclines' cumulative dosage. The E/e' had a significant difference between the two subgroups, which could be attributed to LV diastolic dysfunction caused by anthracyclines. The TAPSE had significant difference between the two subgroups according to different cumulative dosage. Hence, the cumulative dosage of anthracyclines should be controlled <300 mg/m 2 to prevent the subclinical cardiac dysfunction.
In conclusion, this study confirmed that LV GLS is the optimal parameter of LV deformation, which is helpful in the early detection of subclinical LV dysfunction using 2D-STE. The ratio of E and e' is another sensitive parameter that is useful in detecting LV diastolic dysfunction. After anthracyclines' chemotherapy, TAPSE measurement could be used to identify early RV dysfunction. These three parameters showed significant change with different anthracyclines' cumulative dosage, so cumulative dosage should be controlled in clinical treatment.
Financial support and sponsorship
This study was supported by a grant from Research B a c k b o n e Tr a i n i n g F u n d o f B e i j i n g To n g r e n Hospital (No. 2015-YJJ-GGL-009).
Conflicts of interest
There are no conflicts of interest. 
